Clinical Trials Logo

Adrenogenital Syndrome clinical trials

View clinical trials related to Adrenogenital Syndrome.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05927961 Not yet recruiting - Clinical trials for Primary Aldosteronism Due to Aldosterone Producing Adenoma

Spatial Proteomics Profiles of Aldosterone-producing Adenoma and Unilateral Hyperplasia

Start date: August 2023
Phase:
Study type: Observational

Primary aldosteronism (PA) is a common cause of secondary hypertension, which is characterized by excessive aldosterone production by the adrenal gland. Excessive aldosterone can significantly increase the risk of cardiovascular disease and stroke. Patients with aldosterone-producing adenoma (APA) or unilateral hyperplasia (UAH) can be cured by unilateral adrenalectomy. The adrenal cortex is the outer part of the adrenal gland and is subdivided into three layers- the zona glomerulosa, the zona fasciculata, and the zona reticularis. And the outermost layer is the zona glomerulosa, and it's full of cells that make the hormone aldosterone. Although it has been investigated that the main cause of APA or UAH is the mutations of different calcium ion channels, including KCNJ5, CACNA1D, CLCN2 et al, it is still unknown whether there are any other changes of other proteins in different layers. Therefore, the investigators designed the study to characterize the proteomics profiles of adrenal adenoma/hyperplasia leading to primary aldosterone and identify biomarkers for early identification of PA by using spatial proteomics. The samples from adrenal adenoma or hyperplasia will be collected and analyzed by spatial proteomics in Hangzhou Jingjie Biotechnology Co., Ltd. The differentially expressed proteins in different layers will be screened out between APA and UAH, APA and its adjacent normal tissues, and UAH and its adjacent normal tissues, respectively. And KEGG analysis will be conducted to determine enriched pathway in these differentially expressed protein, respectively.

NCT ID: NCT04536662 Not yet recruiting - Clinical trials for Congenital Adrenal Hyperplasia

Comparisons of Different Forms of Glucocorticoid on the Recovery of Reproductive Function in Patients With 21α-hydroxylase Deficiency

CGP21
Start date: October 1, 2020
Phase: Phase 4
Study type: Interventional

The purpose of this study is to conduct an open, randomized controlled clinical trial, evaluating the effects of different dosage forms of glucocorticoid on the Recovery of Reproductive Function in Patients With 21α-hydroxylase Deficiency.

NCT ID: NCT04293133 Not yet recruiting - Clinical trials for Congenital Adrenal Hyperplasia

Final Height in Patients With CAH

Start date: March 11, 2020
Phase:
Study type: Observational

Congenital adrenal hyperplasia (CAH) is the most common inherited disorder in the adrenal gland in children. Growth is usually affected in CAH patients either due to the disease itself or treatment consequences.

NCT ID: NCT04252001 Not yet recruiting - Clinical trials for Growth Hormone Deficiency

Growing up With the Young Endocrine Support System (YESS!)

YESS
Start date: December 1, 2024
Phase: N/A
Study type: Interventional

Transition from paediatric to adult endocrinology is a challenge for adolescents, families and doctors. Up to 25% of young adults with chronic endocrine disorders are lost to follow-up ('drop-out') once the young adult moves out of paediatric care. Non-attendance and sub-optimal medical self-management can lead to serious and expensive medical complications. In a pilot study, adolescents suggested the use of e-technology to become more involved in the transition process. The investigators have designed and developed the YESS! game, a tool to help improve medical self-management in adolescents with chronic endocrine disorders. The hypothesis is that adolescents playing the YESS! game will show a larger increase in self-management score during the first year of transition and will have a lower drop-out rate at the adult endocrine outpatient clinic (OPC), compared to adolescents who do not play the game.

NCT ID: NCT04087148 Not yet recruiting - Clinical trials for Congenital Adrenal Hyperplasia

Linear Growth of Children With Congenital Adrenal Hyperplasia

Start date: September 24, 2019
Phase:
Study type: Observational

The congenital adrenal hyperplasias (CAHs) comprise a family of autosomal recessive disorders that disrupt adrenal steroidogenesis. Three specific enzyme deficiencies are associated with virilization of affected women. The most common form is 21-hydroxylase deficiency (21-OHD) due to mutations in the 21-hydroxylase (CYP21A2) gene. Other virilizing forms include 3b-hydroxysteroid dehydrogenase type 2 (HSD3B2) and 11b-hydroxylase deficiencies associated with mutations in the HSD3B2 and 11b-hydroxylase (CYP11B1) genes, respectively.